NeuroVista Raises $16.5 Million in Equity Financing
Seattle, WA—August 18, 2010—NeuroVista Corporation, a developer of innovative
medical technologies for the management and treatment of epilepsy, today
announced it has closed an equity financing round with total proceeds of $16.5
million. The financing was led by GBS Venture Partners, joined by existing
investors Advanced Technology Ventures, Delphi Ventures and Foundation Medical
Partners. The financing will support the ongoing clinical trials of the
NeuroVista® Seizure Advisory System™ and continued technology development.
"We are very pleased to have GBS join our investor syndicate and we welcome Dr.
Steve Gourlay from GBS to our Board of Directors," said John F. Harris,
President and Chief Executive Officer of NeuroVista. "Steve’s extensive
experience in industry and academic clinical research will be of tremendous
value to us as we move forward with our clinical trials."
"The NeuroVista Seizure Advisory System is a groundbreaking new platform for
empowering people with epilepsy," said Dr. Gourlay. "We believe that NeuroVista
technology will revolutionize the management and treatment of epilepsy by
resolving the uncertainty of when seizures are going to strike, improving
patients’ quality of life, and enabling new models for the use of drug therapy."
About GBS Venture Partners
GBS Venture Partners is a leading life science venture capital firm. Founded in
1996, GBS invests in young businesses developing and commercializing products
which, when combined with the right management and finance, will make a
significant difference to patients' lives and deliver financial returns for its
investors. Particular areas of interest and expertise include medical devices
and human therapeutics. For more information, visit
www.gbsventures.com.au.
About NeuroVista
NeuroVista is a clinical stage medical device company pioneering new
technologies that will revolutionize the management and treatment of epilepsy.
Epilepsy is a neurological condition affecting approximately 1% of the U.S.
population—more than Parkinson’s disease, multiple sclerosis, and Lou Gehrig’s
disease combined. NeuroVista is a privately held company based in Seattle. For
more information, visit
www.neurovista.com.
